Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Michela Piacentini
Observed name:
M. Piacentini
Institutions:
University of Verona,
Vita-Salute San Raffaele University,
Azienda Ospedaliera Universitaria Integrata Verona,
IRCCS Ospedale San Raffaele,
IRCCS San Raffaele Roma
Observed institutions:
University of Verona,
Vita-Salute San Raffaele University,
Azienda Ospedaliera Universitaria Integrata Verona,
IRCCS Ospedale San Raffaele,
IRCCS San Raffaele Roma
ORCID:
0009-0008-2618-7455
Observed ORCID:
0009-0008-2618-7455
OpenAlex ID:
A5066701783
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study
2026
·
Andrea Necchi
, Brigida A Maiorano
, et al.
·
The Lancet Oncology
·
23
A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode
2024
·
Alice Avancini
, Anita Borsati
, et al.
·
The Oncologist
·
17
PDF
Interleukin-8 as a potential prognostic biomarker in renal cell carcinoma: a systematic review and meta-analysis
2025
·
Francesca Zacchi
, Sara Merler
, et al.
·
The Oncologist
·
8
PDF
Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial
2026
·
Andrea Necchi
, Joep J. de Jong
, et al.
·
Journal of Clinical Oncology
·
4
PDF
Adjuvant pembrolizumab plus belzutifan versus placebo in clear cell renal cell carcinoma: a reconstructed survival data analysis of the KEYNOTE-564 and the LITESPARK-022 trials
2026
·
A. Cigliola
, A. Larcher
, et al.
·
ESMO Open
·
2
PDF
Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine
2026
·
Chiara Mercinelli
, Fabrizio Di Costanzo
, et al.
·
Expert Review of Anticancer Therapy
·
2
Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials
2026
·
B.A. Maiorano
, M. Maruzzo
, et al.
·
ESMO Open
·
1
PDF
Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter
2026
·
Emanuele Crupi
, Antonio Cigliola
, et al.
·
Clinical Genitourinary Cancer
·
1
Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy
2026
·
Chiara Mercinelli
, Dean Pavlick
, et al.
·
The Oncologist
·
1
Real-world overall survival (OS) improvements in metastatic urothelial carcinoma (mUC) across three key therapeutic eras.
2026
·
Antonio Cigliola
, Brigida Anna Maiorano
, et al.
·
Journal of Clinical Oncology
·
1
PDF
4791eP Outcomes and characteristics of patients with muscle-invasive bladder cancer (MIBC) enrolled in perioperative therapy trials and radical cystectomy (RC) at San Raffaele Comprehensive Cancer Center
2026
·
B.A. Maiorano
, D. Serafin
, et al.
·
Annals of Oncology
4746P Age at diagnosis as an independent prognostic factor in urothelial carcinoma: Impact on survival and immune microenvironment within molecular subtypes
2026
·
M. Piacentini
, A. Cigliola
, et al.
·
Annals of Oncology
4759P Outcomes of patients with muscle-invasive bladder cancer (MIBC) who declined radical cystectomy (RC) in perioperative therapy trials conducted at San Raffaele Comprehensive Cancer Center
2026
·
C. Mercinelli
, G. Basile
, et al.
·
Annals of Oncology
50 Circulating immature neutrophils are associated with poor response to neoadjuvant therapies in muscle-invasive bladder cancer (MIBC)
2026
·
Camilla Marchigiani
, Giovanni Luigi Pastorino
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial
2026
·
Andrea Necchi
, Chiara Mercinelli
, et al.
·
Nature Medicine
PDF
Real-world overall survival improvements in metastatic urothelial carcinoma across three key therapeutic temporal periods
2026
·
A. Cigliola
, B.A. Maiorano
, et al.
·
ESMO Open
Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy
2026
·
Chiara Mercinelli
, Giuseppe Basile
, et al.
·
Clinical Genitourinary Cancer
Defining the Optimal Therapeutic Approach in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Novel Strategies Versus Gemcitabine-Cisplatin
2026
·
Chiara Mercinelli
, Pietro Scilipoti
, et al.
·
JCO oncology advances.
Neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer: Final results and biomarker analyses of the SURE-01 trial.
2026
·
Brigida Anna Maiorano
, Joep de Jong
, et al.
·
Journal of Clinical Oncology
Molecular characterization of residual disease post-neoadjuvant sacituzumab govitecan (SG), pembrolizumab, or their combination in patients with muscle-invasive bladder cancer (MIBC).
2026
·
Andrea Necchi
, Joep Jacobus de Jong
, et al.
·
Journal of Clinical Oncology
Ip59-11 a Step Forward in Rcc Staging: External Validation of the Eau-proposed M Staging
2026
·
Alessandro Bertini
, Chiara Re
, et al.
·
The Journal of Urology
PDF
Neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC): SURE-02 primary analysis and biomarker results.
2026
·
Andrea Necchi
, Joep Jacobus de Jong
, et al.
·
Journal of Clinical Oncology
Relapsed/refractory clinically advanced (CA) testicular non-seminomatous germ cell tumors (NSGCT): A genomic landscape study.
2026
·
Valentina Tateo
, Antonio Cigliola
, et al.
·
Journal of Clinical Oncology
A0040 A step forward in RCC staging: External validation of the EAU-proposed M staging
2026
·
A. Bertini
, C. Re
, et al.
·
European Urology
A0852 Real-world survival improvements in metastatic urothelial carcinoma (mUC) across three key therapeutic eras
2026
·
A. Cigliola
, B.A. Maiorano
, et al.
·
European Urology
Show more works
View as search
Works count:
29
Citation count:
60
H-index:
4
I10-index:
2
Year
Topic
Type